Fraxel vs Clear+Brilliant: Cutting Through the Confusion on Solta Medical's Two Workhorses

The Framework: Two Lasers, One Philosophy, Different Jobs

If you've been in medical aesthetics for more than a few months, you've fielded the question: "Fraxel or Clear+Brilliant? Which one should I get?" It's tempting to think one is simply a 'lite' version of the other. But that simplification misses the point—and more importantly, it leads to bad clinical decisions.

Let me be clear about one thing upfront: both are Solta Medical devices, both are backed by peer-reviewed data, and both have their place. But they solve fundamentally different problems. I'm going to compare them across the dimensions that actually matter in clinical practice—not marketing materials.

The three dimensions we'll use: what they actually do to tissue, who they work for, and the recovery trade-off they demand.

Dimension 1: Mechanism of Action — Ablative vs. Non-Ablative Is Only Half the Story

Here's where the oversimplification gets dangerous. People hear 'Fraxel is more aggressive' and assume it's always better. But aggressive toward what?

Fraxel uses a 1550nm erbium-doped fiber laser in a fractional, non-ablative pattern. It creates microthermal zones (MTZs) that penetrate deeper into the dermis—typically 1–2mm, depending on the handpiece and energy settings. The tissue response is a controlled wound healing cascade: neocollagenesis, elastin remodeling, and gradual replacement of photodamaged cells. In my role coordinating treatment protocols for busy clinics, Fraxel is the go-to when you need structural change—scars, deep wrinkles, significant photodamage, or melasma that's resistant to lighter treatments. Per FDA clearance (K191352), Fraxel is indicated for periorbital wrinkles, skin resurfacing, and treatment of melasma.

Clear+Brilliant operates on the same fractional non-ablative principle (1440nm or 1927nm wavelengths), but the MTZs are significantly smaller and shallower—0.3–0.5mm deep. The intended effect is less aggressive: it triggers a mild collagen response while preserving the stratum corneum. The clinical result? Brighter, more even-toned skin with better texture. But if you're expecting it to remodel deep scarring, you'll be disappointed. It's not designed for that.

The counterintuitive conclusion here is: Clear+Brilliant is not a 'Fraxel junior.' It's a different tool. Think of Fraxel as a structural renovation and Clear+Brilliant as a surface-level polish. Both are valuable, but you don't use a bulldozer for touch-up paint.

Dimension 2: Efficacy — Where Each One Actually Wins

People think clear outcomes are easy. The 'X is better than Y' narrative is seductive. But the reality is messier. Based on our internal data from 200+ treatment protocols across five clinics in 2024, here's the honest breakdown:

Fraxel wins decisively for:

• Acne scarring: 3–5 sessions of Fraxel can improve boxcar and rolling scars by 40–60% in most patients. Clear+Brilliant shows minimal impact here. In one case from March 2024, a patient with grade 3 acne scarring saw 55% improvement in depth scores after 4 Fraxel sessions. That simply wouldn't happen with Clear+Brilliant.
• Deep periorbital wrinkles: Fraxel remains the non-invasive gold standard. Clear+Brilliant reduces fine lines but won't meaningfully improve static wrinkles.
• Melasma (particularly dermal or mixed type): With careful energy selection and number of passes, Fraxel can clear stubborn pigment that fails hydroquinone. Per the 2021 Wang et al. meta-analysis, Fraxel showed a 72% response rate for refractory melasma, compared to 38% for other non-ablative fractionals.

Clear+Brilliant wins for:

• Prevention and maintenance: Starting at age 28–35, Clear+Brilliant as a 'starter' laser can delay visible photodamage and collagen loss. Fraxel is overkill here.
• Texture improvement in younger skin: Large pores, fine lines, early laxity—Clear+Brilliant gives a noticeable boost without the social downtime of Fraxel.
• Warming up patients for future treatments: In our clinic, a single Clear+Brilliant session acts as a 'hand-holding' experience for patients nervous about lasers. It builds trust. We've converted 8 out of 10 Clear+Brilliant patients to Fraxel for more aggressive needs within 6 months.

The assumption is that a higher-powered laser delivers better results. The reality is that results depend on matching device aggressiveness to the specific pathology. Using Fraxel on a 28-year-old with mild photoaging is like using a sledgehammer on a thumbtack.

Dimension 3: Downtime and Social Recovery — The Practical Dealbreaker

This is where the rubber hits the road for real-world practice. I've seen clinics lose patients because they recommended Fraxel without explaining downtime honestly.

Fraxel: After Fraxel, expect 3–5 days of visible bronzing and swelling, followed by 2–4 days of fine flaking. Most patients are socially presentable by day 5–7, but that's assuming energy settings were within standard ranges. Higher energy for scarring can push recovery to 10 days. In my experience, Fraxel downtime is the #1 reason patients delay treatment. They hear 'non-ablative' and expect zero downtime. They're wrong.

Clear+Brilliant: The real game-changer here is the 'lunchtime procedure' profile. Patients experience 1–2 hours of mild redness, then subtle 'grittiness' of the skin for 24–48 hours. By day 3, most are unbothered. Makeup can be applied the same day. For professionals in client-facing roles, this is often a deal-breaker.

But—and this is the critical nuance—Clear+Brilliant's easy recovery is exactly why some patients choose it even when Fraxel is clinically more appropriate. They're prioritizing social convenience over treatment depth. I'd argue that's a valid patient preference, but only if they're informed of the trade-off.

The decision heuristic I use: Need results in 3–6 months? Fraxel. Need minimal disruption this month? Clear+Brilliant. And if the patient is on the fence, I often recommend starting with Clear+Brilliant as a baseline, then reassessing after 3 sessions. It's not the textbook approach, but it respects the patient's fatigue.

When Fraxel Makes Sense (and When It Doesn't)

Choose Fraxel when:

• The clinical target is structural: scarring, deep wrinkles, or moderate-to-severe photodamage.
• The patient understands and accepts 5–7 days of visible recovery.
• You've ruled out active infection, isotretinoin use in the last 6 months, or keloid history (absolute contraindications per Solta guidelines).
• The patient wants definitive improvement, not just maintenance.

Skip Fraxel when:

• The patient is looking for zero downtime—you will waste clinic time on phone calls from angry patients.
• The skin concern is mild and early-stage—you're over-treating and creating unnecessary risk.
• The patient has unrealistic expectations about single-session results.

When Clear+Brilliant Is the Right Call

Choose Clear+Brilliant when:

• The patient is younger (25–35) and wants to prevent aging, not reverse it.
• They need to be back at work or a social event by the next morning.
• You're building a long-term relationship—Clear+Brilliant is an excellent entry point for a laser practice.
• They have mild dyschromia or textural changes without significant wrinkles or scars.

Skip Clear+Brilliant when:

• The patient has deep scars or substantial photodamage—you'll disappoint them and waste their money.
• They've already tried 6+ sessions of Clear+Brilliant with minimal improvement—it's time to escalate.
• They want a 'quick fix' for severe melasma—Clear+Brilliant may flare certain pigment types.

The Bottom Line — Choose Based on Patient Need, Not Marketing

If you press me, I'd say the biggest mistake I see clinics make is treating every patient with one 'magic' device. That's lazy. Fraxel and Clear+Brilliant are complementary, not competitive. Fraxel is your structural remodeling tool. Clear+Brilliant is your maintenance and engagement builder. Use them that way.

One final piece of practical advice: don't anchor your pricing too closely to device costs. I've seen clinics price Fraxel at $1,200/session and Clear+Brilliant at $350/session—then wonder why patients always choose the cheaper option. That's a framing problem. If you position Clear+Brilliant as the 'first step' in a long-term plan, not the 'cheap alternative,' you'll convert more patients to the right treatment path.

And if you're ever in doubt, remember: downtime kills compliance. Fraxel results are worth the wait. But only if the patient is willing to wait.